PGI24 Cost-Effectiveness Analysis of 48-Week Peginterferon Alpha-2a Under RGT Strategy Versus 3 Years Entecavir for the Treatment of HBeAg-Positive Chronic Hepatitis B in China
Abstract
Authors
W. Zhang H. Zhuang H. Ren X. Dou W. Chen